Holen Sie sich die Stockscreener-App
43.95
0.17%
0.0675
Schlusskurs vom Vortag:
$43.88
Offen:
$43.65
24-Stunden-Volumen:
984.75K
Relative Volume:
0.37
Marktkapitalisierung:
$11.41B
Einnahmen:
$2.32B
Nettoeinkommen (Verlust:
$782.57M
KGV:
15.79
EPS:
2.7838
Netto-Cashflow:
$875.84M
1W Leistung:
+4.77%
1M Leistung:
+5.80%
6M Leistung:
+9.85%
1J Leistung:
+27.14%
1-Tages-Spanne:
$43.55
$44.16
1-Wochen-Bereich:
$42.42
$44.19
52-Wochen-Spanne:
$32.38
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
43.95 | 11.40B | 2.32B | 782.57M | 875.84M | 2.7838 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-11-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Stock Report: Can Exelixis Inc sustain its profitability2026 Fundamental Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Nisa Investment Advisors LLC Has $6.16 Million Holdings in Exelixis, Inc. $EXEL - MarketBeat
Here's why Exelixis (EXEL) is a strong growth stock - msn.com
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Tema Etfs LLC Grows Position in Exelixis, Inc. $EXEL - MarketBeat
Allspring Global Investments Holdings LLC Has $60.31 Million Position in Exelixis, Inc. $EXEL - MarketBeat
Moving Averages: Is Exelixis Inc a play on infrastructure spendingGlobal Markets & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance UK
Exelixis: A Strong Contender in the Cancer Drug Market - The Globe and Mail
Kidney Cancer Drugs Market to Grow by $2 Billion During - GlobeNewswire
Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry - Yahoo Finance
Exelixis Inc. (NASDAQ:EXEL) Presents a Compelling Value Investment Case - ChartMill
Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Trading Systems Reacting to (EXEL) Volatility - Stock Traders Daily
Exelixis, Inc. $EXEL Stake Lowered by Assenagon Asset Management S.A. - MarketBeat
RBC Capital lowers Exelixis (EXEL) price target to $43 - MSN
MIC:EXEL-RM OCF Yield %: 8.20 — 52% Above Median - GuruFocus
Exelixis, Inc. $EXEL Shares Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat
RBC Capital Lowers Exelixis (EXEL) Price Target to $43 - Insider Monkey
15 Set-It-and-Forget-It Stocks to Buy in 2026 - Insider Monkey
Exelixis (MIC:EXEL-RM) NonCurrent Deferred Revenue : ₽0.00 Mil (As of Dec. 2025) - gurufocus.com
EXEL Technical Analysis | Trend, Signals & Chart Patterns | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
EXEL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vanguard disaggregates holdings; Exelixis (NASDAQ: EXEL) shows 0 shares - Stock Titan
Exelixis (NASDAQ:EXEL) Raised to Strong-Buy at Truist Financial - MarketBeat
Exelixis, Inc. $EXEL Shares Sold by Nordea Investment Management AB - MarketBeat
Exelixis Inc at TD Cowen Healthcare Conference Transcript - gurufocus.com
EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM - GuruFocus
EXEL Stock Price, Quote & Chart | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
Quarterly Trades: Will Exelixis Inc outperform its industry peersMarket Volume Report & Capital Protection Trade Alerts - baoquankhu1.vn
Private Client Services LLC Takes $1.99 Million Position in Exelixis, Inc. $EXEL - MarketBeat
Here's why Exelixis (EXEL) is a strong value stock - MSN
Strategic Investment Advisors MI Buys 27,659 Shares of Exelixis, Inc. $EXEL - MarketBeat
How Exelixis Inc. (EXEL) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Pharma Stocks Analysis 2026: Pfizer & Novo Nordisk Rebound, Exelixis GrowthNews and Statistics - IndexBox
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
The Best Healthcare Stocks to Buy With $50 Right Now - The Motley Fool
Portfolio Update: What is the earnings history of Exelixis Inc2026 Highlights & AI Powered Trade Plan Recommendations - baoquankhu1.vn
L2 Asset Management LLC Invests $3.36 Million in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (EXEL) Valuation After Earnings Beat FDA Progress And Cabometyx Label Expansion - Yahoo Finance
Exelixis, Inc. $EXEL Shares Acquired by Clark Capital Management Group Inc. - MarketBeat
Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink - MarketBeat
Exelixis Highlights CABOMETYX Growth, Zanzalintinib PDUFA and Pipeline Strategy at Barclays Conference - MarketBeat
Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference - MarketBeat
Exelixis Inc Stock (ISIN: US30161Q1040) Gains Momentum on Earnings Beat and Zanzalintinib FDA Milest - AD HOC NEWS
Capital Impact Advisors LLC Boosts Stock Position in Exelixis, Inc. $EXEL - MarketBeat
How Exelixis’ Earnings Beat and FDA Zanzalintinib Milestone Will Impact Exelixis (EXEL) Investors - simplywall.st
Exelixis, Inc. $EXEL Stake Raised by South Street Advisors LLC - MarketBeat
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):